Incidence of cytomegalovirus DNAemia in pediatric kidney, liver, and heart transplant recipients: Efficacy and risk factors associated with failure of weight‐based dosed valganciclovir prophylaxis
Pediatric Transplantation · 2023
DOI: 10.1111/petr.14493 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Transplantation, 2023. Verfasst von Rochelle Liverman und 8 weiteren Autor:innen. Beteiligte Einrichtung: Children's Healthcare of Atlanta, Georgia, Atlanta, USA. Hauptthemen laut MEDLINE: Cytomegalovirus Infections, Heart Transplantation. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Abstract (Originalsprache)
Background
Cytomegalovirus (CMV) is associated with morbidity and mortality in solid organ transplant recipients (SOTR). Valganciclovir (VGC) is extensively used for prophylaxis. Optimal dosing in children, risk factors for failure, and the impact of dose adjustments on CMV DNAemia is not well established.
Methods
This retrospective cohort study of pediatric SOTR transplanted between 2010–2018 evaluated the epidemiology of CMV DNAemia and used Cox‐regression to assess the risk factors for CMV DNAemia within one‐year following SOTR.
Results
In 393 pediatric SOTR (heart [96, 24.4%], kidney [180, 45.6%], liver [117, 29.8%]; median age 9.5 ± 0.3 years), overall CMV DNAemia incidence was 6.6/10 000 days (95%CI 5.1/10 000–7.9/10 000) and varied by organ groups: heart 8.2/10 000 days (95%CI 4.9/10 000–11.4/10 000), kidney 5.8/10 000 days (95%CI 3.9/10 000–7.8/10 000), liver 6.2/10 000 days (95%CI 3.7/10 000–8.7/10 000). CMV DNAemia was detected in 75 of 275 (27.2%) patients who received prophylaxis (40 cases occurred during prophylaxis and 35 occurred after completion of prophylaxis). The median VGC dose given according to institutional weight‐based algorithm was approximately 1.5‐fold lower than the manufacturer‐recommended dose. This discordance was more prominent at younger age groups (3.2‐fold lower in
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Children's Healthcare of Atlanta, Georgia, Atlanta, USA.
- Joe DiMaggio Children's Hospital, Florida, Hollywood, USA.
- Division of Pediatric Nephrology, Emory University School of Medicine, Georgia, Atlanta, USA.
- Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Emory University School of Medicine, Georgia, Atlanta, USA.
- Division of Pediatric Cardiology, Children's National Hospital, DC, Washington, USA.
- Division of Pediatric Cardiology, Emory University School of Medicine, Georgia, Atlanta, USA.
ORCID-Profile: Roshan George, Shriprasad Deshpande, Chad Mao, Inci Yildirim
Zitieren
APA
Liverman, R., Serluco, A., Nance, G., George, R., Rodriguez, D. S., Deshpande, S., Mao, C., Garro, R., & Yildirim, I. (2023). Incidence of cytomegalovirus DNAemia in pediatric kidney, liver, and heart transplant recipients: Efficacy and risk factors associated with failure of weight‐based dosed valganciclovir prophylaxis. Pediatric Transplantation. https://doi.org/10.1111/petr.14493
Vancouver
Liverman R, Serluco A, Nance G, George R, Rodriguez DS, Deshpande S, et al. Incidence of cytomegalovirus DNAemia in pediatric kidney, liver, and heart transplant recipients: Efficacy and risk factors associated with failure of weight‐based dosed valganciclovir prophylaxis. Pediatric Transplantation. 2023. doi:10.1111/petr.14493
BibTeX
@article{Liverman2023,
author = {Liverman, Rochelle and Serluco, Anastacia and Nance, Gwen and George, Roshan and Rodriguez, Dellys Soler and Deshpande, Shriprasad and Mao, Chad and Garro, Rouba and Yildirim, Inci},
title = {Incidence of cytomegalovirus DNAemia in pediatric kidney, liver, and heart transplant recipients: Efficacy and risk factors associated with failure of weight‐based dosed valganciclovir prophylaxis},
journal = {Pediatric Transplantation},
year = {2023},
doi = {10.1111/petr.14493}
}
EUVIMED